Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Deutsche Schmerzgesellschaft

InstitutionResearch output, impact & collaborations

Deutsche Schmerzgesellschaft is a research organisation in Berlin, DE. OpenAlex records 1,130 works and 41,782 citations for it. 330 researchers list it as their most recent affiliation.

1,130
Works
41,782
Citations
330
Researchers
56
Avg h-index

How has Deutsche Schmerzgesellschaft's publication output changed over time?

ScholarIQpublication output · 2016–2024

Output grew100% over the shown period — from 1 works in 2016 to 2 in 2024.

1
1
2
2
2016202120232024

What are the most-cited papers on Deutsche Schmerzgesellschaft?

ScholarIQmost cited works
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
New England Journal of Medicine. 20211,781 CitationsOPEN ACCESS
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T. Powles, Laurence Albigès, Axel Bex, Éva Compérat, Viktor Grünwald, Ravindran Kanesvaran, H. Kitamura, R. McKay, Camillo Porta, G. Procopio, Manuela Schmidinger, Cristina Suárez, Jeremy Yuen‐Chun Teoh, Guillermo de Velasco, Matthew R. Young, Silke Gillessen
Annals of Oncology. 2024326 CitationsOPEN ACCESS
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
David Cella, Viktor Grünwald, Paul Nathan, Justin Doan, Homa Dastani, Fiona Taylor, Bryan Bennett, Michael DeRosa, Scott Berry, Kristine Broglio, Elmer Berghorn, Robert J. Motzer
The Lancet Oncology. 2016220 Citations
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J. Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Żurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C. Goh, Dingwei Ye, Alejo Lingua, Jean‐Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey A. Sosman, Michael Staehler, Sergio Vázquez Estévez, Burçin Şimşek, Julia Spiridigliozzi, Aleksander Chudnovsky, Axel Bex
The Lancet. 2023180 CitationsOPEN ACCESS
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, B. Yа. Alekseev, Sun Young Rha, Jaime R. Merchan, Jeffrey C. Goh, Aly‐Khan A. Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung‐Hoo Hong, Howard Gurney, María José Méndez, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso‐Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph E. Burgents, Cixin He, Chinyere E. Okpara, Jodi A. McKenzie, Toni K. Choueiri, for the CLEAR Trial Investigators, Robert J. Motzer, Toni K. Choueiri, Thomas E. Hutson, Luke T. Nordquist, David R. Spigel, Jaime R. Merchan, Saby George, Sandhya Srinivas, Brendan D. Curti, Andrew Pippas, Elisabeth I. Heath, Subramanya Rao, Theodore Stewart Gourdin, Mehmood Hashmi, Nafisa Burhani, Ana M. Molina, Alan J. Koletsky, Robert Alter, C. Alemany, Benjamin A. Gartrell, Mike Cusnir, Harsha Vyas, Stephanie L. Graff, Christian Squillante, Mark Knapp, Ivor Percent, Vijay Patel, Daniel L. Spitz, C. Harkness, Marc Matrana, Lindsay Overton, Stephen Richey, Donald Richards, Habib M. Ghaddar, Robert Galamaga, Ralph J. Hauke, Joseph Haggerty, Ronald Harris, Mark Johns, Samith T. Kochuparambil, Christian Kollmannsberger, Bobby Shayegan, Christina Canil, Eric Winquist, Catherine Sperlich, Georg A. Bjarnason, Naveen S. Basappa, Wolfgang Loidl, Wolfgang Horninger, Manuela Schmidinger, Lionel D’Hondt, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolická, Jiří Tomášek, Jana Prausová, Tomáš Büchler
Journal of Clinical Oncology. 2024170 CitationsOPEN ACCESS

How much of the research on Deutsche Schmerzgesellschaft is open access?

ScholarIQopen access share
83%OPEN ACCESS
Gold
0%
Green
33%
Hybrid
33%
Bronze
17%
Closed
17%

Related on ScholarIQ

Clinical practice guidelines implementation
Top Topic
Health and Medical Studies
Top Topic
Health Systems, Economic Evaluations, Quality of Life
Top Topic
Medical Practices and Rehabilitation
Top Topic
Economic and Financial Impacts of Cancer
Top Topic
Cancer survivorship and care
Top Topic
470M+ articles · free account